Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQNDdBQWp0eXhySGlJdTloSFcwMVk1WmY1NzVlZldsRDZRTjRRdy0zTHVCbXU5QjRlSWdFWmI2OGNXNmN6SHp2dF9oOEItN1E2dl9kSnZjZVYwT096T1V0aUpvT0pzX29aWVhILVBLMDdZMkRQX2VsZHBrRUJuT3phY1MzQ2Rlcy12OEZWTm9XWG12YmZDVkI1cU1ObWtzNzJOcEN1MklZZ2dQWWxMRGJMQThLZFdFZw?oc=5" target="_blank">Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
BASF considers raising offer for Evonik, sources say - Reuters
BASF considers raising offer for Evonik, sources say Reuters
October 9, 2026 at 02:02 PMArgenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PMNvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom - Reuters
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom Reuters
October 8, 2026 at 06:18 PMViatris bets on non-opioid pain drugs with $1.65 billion Pacira deal - Reuters
Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal Reuters
October 8, 2026 at 02:39 PMPepsiCo to cut costs as weak N.America business hurts core profit forecast - Reuters
PepsiCo to cut costs as weak N.America business hurts core profit forecast Reuters
October 8, 2026 at 11:26 AMLevi Strauss lifts annual profit outlook on tariff refunds, holiday demand - Reuters
Levi Strauss lifts annual profit outlook on tariff refunds, holiday demand Reuters
October 7, 2026 at 10:10 PM